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ABSTRACT 
 
Influenza infection of distal airways in human lungs is linked to an increased risk of 
death. Intercellular communication between resident alveolar epithelial cells (AECs) and 
alveolar macrophages (AMs) plays an essential role in the body’s innate defense 
against inhaled pathogens. Extracellular vesicles (EVs) are small, double membrane-
bound packages of proteins, lipids, and RNAs secreted by nearly all cell types. They 
modulate physiologic functions in a variety of contexts. AM-derived EV (AM-EV) 
communication is an emerging example of intercellular communication at this site but 
has not been explored in the context of host defense against influenza. Unpublished 
background data prompting the studies in this thesis demonstrate that uptake of AM-
EVs protect AECs against influenza infection at an early, intracellular stage of the viral 
replication cycle. This activity of AM-EVs was present against only a subset of influenza 
strains studied and depended on the specific hemagglutinin expressed by the strain. 
The early, intracellular stage of the influenza replication cycle mediated by 
hemagglutinin is endosomal fusion. Therefore, we hypothesized that AM-EVs inhibit the 
endosomal fusion of susceptible influenza strains, preventing their translocation into and 
replication within the nucleus. To test this, we performed confocal immunofluorescence 
studies to evaluate the effect of AM-EVs on the localization of differentially-inhibited 
influenza strains to late (acidified) endosomes. Furthermore, in these strains, we 
characterized their relative sensitivity to endosomal acidification inhibitors and 
established the kinetics of their escape from late endosomes. In sensitive strains, AM-
EVs inhibit influenza infection in AECs at the point of viral-endosomal fusion, trapping 
the virus in late (acidified) endosomes. Additionally, sensitive strains escape the 
endosome earlier, suggesting that the pH of viral-endosomal fusion of susceptible 
strains is higher than that of resistant strains. These results suggest that AM-EVs drive 
endosomal pH to an acidic range facilitating fusion of resistant strains, but outside the 
optimal fusion pH range of susceptible strains. By defining the stage of infection 
targeted by AM-EVs, this will inform future studies toward the identification of 
responsible mediators within EVs as well as efforts to improve antiviral therapies. 
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INTRODUCTION 
 
Alveoli are the thin-walled, sac-like structures located in the distal airways of the lung. 
Their primary function is to exchange gases between the bloodstream and air inhaled 
into the alveolar space. The microenvironment of these distal air spaces is one plagued 
with homeostatic challenges for their resident cell types. Routinely exposed to airborne 
antigens and infectious diseases such as influenza, the niche of cells at this site must 
combat these threats while prohibiting an inflammatory response great enough to be 
detrimental to their function. 
 
Influenza is a potentially life-threatening virus that infects the respiratory tract of several 
mammalian species, including humans. In the 2017-2018 season alone, 61,000 people 
died as a consequence of influenza, worldwide Centers for Disease Control and 
Prevention Foundation [CDC], 2019). Influenza causes great strife in both the health 
care and research communities due to the morbidity and mortality associated with this 
infection. Influenza-associated costs to the US alone total nearly 100 billion dollars 
annually (CDC, 2014). There are currently 4 types of influenza that have been 
classified: Influenza A (IAV), B, C, and D Virus. IAVs are of primary concern to health 
care providers and researchers, as 75% of influenza cases are caused by IAVs 
(Nyirenda et al., 2016). IAVs primarily infect the cells residing in the large, or proximal, 
airways (CDC, 2017). However, infection may progress to the smaller, distal airways of 
the lung and lead to infection of the alveoli. It is infection at this site that is associated 
with an increased risk of death (Oslund et al., 2011). Here, we study a mechanism by 
which resident innate immune cells combat an influenza infection at this vital site.  
 
Alveolar macrophages (AMs) are the primary phagocytic cell type at this site and are 
known to initiate inflammatory responses in alveoli (Peters-Golden, 2004; Rubins, 
2003). Resident AMs possess several protective innate immune functions in the 
alveolar space, such as clearance of microbes (Peters-Golden, 2004). In the context of 
influenza infection, AMs have been shown to play an important role in host defense 
through various means: 1) AMs infected with influenza secrete pro-inflammatory 
cytokines in order to combat the infection (Seo et al., 2004); 2) AMs ingest apoptotic 
bodies created by a productive influenza infection (Duan et al., 2017); and 3) AMs 
sequester influenza virions without enabling productive replication in themselves (Duan 
et al., 2017). However, despite being one of two primary cell types in the alveolar space 
and the resident innate immune cell at this site, recent studies have shown that there is 
only one AM per 3 alveoli (Bhattacharya et al., 2016). Additionally, AMs have been 
shown to be relatively immobile in vivo (Westphalen et al., 2014). These findings 
suggest a necessity for AMs to use paracrine signaling to maintain homeostasis at this 
site; however, AM paracrine signaling in the context of influenza infection has yet to be 
explored.  
 
One form of paracrine signaling which AMs utilize that has recently gained momentum 
in the research community is mediated by extracellular vesicles (EVs). EVs are small 
(<1μm), double membrane-bound compartments originating from endosomal or plasma 
membranes and secreted by all cell types (Margolis and Sadovsky, 2019). Several 
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subtypes of EVs have been defined based primarily on size; exosomes (50-100nm 
vesicles derived from multivesicular bodies), microparticles (200nm-1μm vesicles 
resulting from plasma membrane budding), and apoptotic bodies (formed from 
membrane disintegration) are considered three of the main EV classifications (Margolis 
and Sadovsky, 2019). Originally thought to solely be a means of excreting unnecessary 
molecules from the parent cell (Margolis and Sadovsky, 2019), it is now known that EVs 
transport functional proteins, nucleic acids, and lipids to adjacent or distant cells 
(Margolis and Sadovsky, 2019). EVs are used to communicate with and able to alter the 
physiology of recipient cells (Margolis and Sadovsky, 2019). In the distal airways, 
specifically, EVs isolated from AMs (AM-EVs) play an important role in maintaining 
homeostasis. As Speth et al. demonstrated, AM-EV packaging of a cytokine suppressor 
(SOCS3) is influenced by the presence of bioactive mediators that create an 
environment that mimics acute lung injury (2016). Additionally, Schneider et al. 
demonstrated that AECs control their uptake of AM-EVs in response to environmental 
factors (2017). The controlled packaging and uptake of AM-EVs make them ideal 
particles for modulating the host’s response to viral infections.  
 
Notably, the role of EVs in the spread of disease pathology and viral infection is a 
double-edged sword (Rubins, 2003). Several studies have implicated this form of 
intercellular communication in mediating the spread of many diseases and infections 
(Meckes and Raab-Traub, 2011; Asai et al., 2015; Rudnick et al., 2017). During viral 
infections, specifically, EVs can favor the host or the virus. In some infections, EVs 
released from infected cells have been shown to carry viral and/or host factors that 
ultimately facilitate productive infection of the recipient cell (Madison et al., 2015; Liu et 
al., 2014; Fu et al., 2017) or induce apoptosis in uninfected cells (Lenassi et al., 2010). 
Conversely, several studies have demonstrated a protective role of EVs against viral 
infections such as influenza. EVs derived from AECs are able to deliver functional host 
and viral cargo, inducing interferon production in recipient AECs and subsequently 
inhibiting influenza infection (Liu et al., 2019). Additionally, EVs isolated from 
bronchoalveolar lavage fluid were recently shown to differentially express several 
microRNAs and, consequently, upregulate pro-inflammatory cytokines during influenza 
infection (Maemura et al., 2018). Despite the evidence that EVs play a role in host 
immune responses and the apparent necessity for AM paracrine signaling to mediate 
pro- and anti-inflammatory responses at this site, nothing is known about the explicit 
role of AM-EVs in the host’s response to influenza.  
 
To better understand AM paracrine signaling in host response to influenza infection of 
alveoli, our lab investigated the role of AM-EVs (which we will simply refer to as “EVs” 
for the rest of this paper for the sake of simplicity) in the context of influenza infection of 
AECs. Our lab (Schneider et al., unpublished data) found that:  
- Secreted mediators from AMs inhibit influenza infection of epithelial cells, and 
this inhibitory activity localizes to EVs. 
- EVs isolated from mouse AMs and human macrophages also demonstrate this 
inhibitory effect against influenza infection. 
- EVs inhibit influenza infection of both canine kidney epithelial (MDCK) cells – the 
classical cell line used in influenza research – and AECs. 
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- EVs inhibit influenza infection in AECs in vitro and in vivo. 
The lab further characterized the mechanism by which EVs inhibit influenza infection of 
AECs and found that:  
- Influenza infection is inhibited by EVs at an intracellular stage. 
- Inhibition of influenza infection by EVs does not occur within 1 hour of infection of 
epithelial cells, but consistently occurs within 3 hours of infection, thus providing 
data regarding the timing of inhibition in reference to a single replication cycle of 
influenza (~6 hours, total).  
- The inhibitory activity of EVs depends on the subtypes of the viral surface 
proteins hemagglutinin (HA) and neuraminidase (NA) expressed by the influenza 
strain.   
The goal of the studies in this thesis were to 1) validate Schneider et al.’s unpublished 
findings regarding HA-/NA-specific differential strain sensitivity to EVs; 2) identify the 
stage of viral replication targeted by EVs; and 3) identify a means of their inhibitory 
activity. 
  
By identifying the stage of replication targeted by EVs, we anticipated being in a better 
position to identify the mechanism of inhibition of influenza by EVs. Notably, the proteins 
HA and NA are essential to several stages of the viral replication cycle and are major 
determinants of IAV infectivity, transmissibility, and pathogenicity (Sakai et al., 2017). 
While several HA and NA isotypes exist, H1N1 and H3N2 combinations are endemic 
culprits for both seasonal (similar, recurring strains against which most people have 
some immunity built) and pandemic (new strains that arise from mutations against 
which most people have no built immunity) influenza in the human population (Dou et 
al., 2018). As such, these strains of IAV were of primary concern to our research efforts.   
 
NAs are enzymes capable of cleaving sialic acid, a sugar located on the terminal ends 
of many glycoproteins and glycolipids (Cohen et al., 2013; Yang et al., 2014). These 
glycoproteins and glycolipids coat cell surfaces and reside within mucus membranes 
(Cohen et al., 2013; Yang et al., 2014). HA is a protein that binds to receptors on cell 
surfaces of mucus membranes within the upper respiratory tract via interaction with the 
terminal sialic acids of these viral-receiving glycoproteins (Sakai et al., 2017). The 
combined functions of HA and NA are, therefore, essential in mediating viral 
progression through mucus membranes in order to reach and bind to target cells. While 
HA is known to mediate viral entry into the target cell through receptor-mediated 
endocytosis, Schneider et al. was able to eliminate the possibility of EVs preventing viral 
surface binding as the mode of viral inhibition (unpublished data), urging us to look at a 
later HA-/NA-dependent stage in the replication cycle. Upon internalization, the virion 
enters and is trafficked through the cell within an endosome - a small, membrane-bound 
compartment of the cell that originates from intracellular budding of the plasma 
membrane. Endosomes move inwards from the cell periphery and undergo a regulated 
process of gradual acidification during this journey to a late (acidified) endosome in 
order to prepare to merge with their ultimate destination: the lysosome (Elkin et al., 
2016). However, before the virion-containing endosome reaches the lysosome, the low 
pH of the late endosome induces a conformational change in HA. This change enables 
fusion of the viral envelope with the endosomal membrane and, consequently, enables 
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release of the influenza RNA into the cytoplasm. The viral RNA then translocates into 
the nucleus and hijacks host cell transcription and translation machinery to assemble 
new viral molecules. These viral molecules assemble at the intracellular surface and 
bud from the plasma membrane in a NA-dependent manner (Shtyrya et al., 2009). 
Newly-released viral clones then repeat the cycle, locating and infecting other cells. The 
time necessary to complete one full replication cycle from the time of entry to production 
of new virus varies slightly among strains, but usually only takes about 6 hours (World 
Health Organization [WHO], 2020). Given that the replication cycle of influenza is about 
6 hours, Schneider et al.’s finding that EVs inhibit influenza within 3 hours of infection 
(unpublished data) suggested that the stage of influenza inhibited by EVs is before 
plasma membrane budding of new viral molecules. With the additional knowledge that 
EVs inhibit influenza at an HA- or NA-dependent stage of the replication cycle 
(Schneider et al., unpublished data), we hypothesized that EVs inhibit fusion of 
susceptible strains with the endosomal membrane early in infection. Under the 
assumption that EVs inhibit viral-endosomal fusion, we hypothesized that EVs did so via 
manipulation of endosomal pH, given the pH-dependent conformational change 
required in HA for influenza to progress beyond this stage of the replication cycle.  
 
To test these hypotheses, we first confirmed that the antiviral effect of EVs is solely due 
to variances in HA or NA using reassortant viral strains. To understand the role of EVs 
on influenza at the point of viral-endosomal fusion, we performed confocal 
immunofluorescence studies to evaluate the colocalization of influenza nucleoprotein 
(NP) with the late endosomal marker Rab-7. Finally, we performed endosomal 
acidification inhibitor assays and timed endosomal escape assays using the acidification 
inhibitors bafilomycin and/or chloroquine to distinguish strain differences in the pH of 
viral-endosomal fusion. We found that EVs inhibit influenza replication in AECs at the 
point of viral-endosomal fusion, trapping the virus in late (acidified) endosomes. Our 
studies suggested that EVs likely inhibit this stage of viral replication by reducing 
endosomal pH to a point beyond which susceptible strains are not able to fuse with the 
endosomal membrane. By identifying the stage of replication targeted by EVs and their 
mode of inhibition at this stage, we hope to inform the identification of responsible 
mediators within EVs as well as efforts to improve antiviral therapies. 
 
MATERIALS AND METHODS 
 
Statistical Analysis and Data Presentation 
Statistical analysis was performed between means of condition replicates unless 
otherwise noted. Experiments were performed in triplicates unless otherwise noted. 
Data analysis was performed using GraphPad Prism 8.0 software and utilized One-way 
ANOVA with Turkey’s multiple comparison post hoc analysis or Student’s t-test where 
appropriate. All individual data points within each condition is displayed in figures for 
transparency. Statistical significant was set at p < 0.05. The following symbols were 
used to display p value ranges: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
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Reagents, Cell Lines, and Culture Medium 
MDCK cells (ATCC) were cultured in DMEM (Gibco) supplemented with 10% FBS and 
penicillin/streptomycin (Invitrogen) unless otherwise noted. A549 adenocarcinoma 
human alveolar basal epithelial cells (ATCC) and MH-S AMs (ATCC) were cultured in 
RPMI 1640 without L-glutamine (GIBCO) supplemented with 10% FBS and 
penicillin/streptomycin (Invitrogen) unless otherwise noted. Viral infections occurred in 
viral growth medium (VGM): DMEM supplemented with 2mg/mL TPCK-treated trypsin 
(Sigma); 25mM HEPES (GIBCO Cat. #15630); 0.1875% BSA (Sigma); and 
penicillin/streptomycin (Invitrogen). Acidification inhibitors bafilomycin (B 1793) and 
chloroquine (C6629-25G) were purchased from Sigma. Bafilomycin was reconstituted in 
100% DMSO and stored in -80°C. Working dilutions of bafilomycin and corresponding 
controls were diluted to 0.1% DMSO in cell culture medium. Chloroquine was 
reconstituted in sterile water and stored in -80°C.  
 
Viruses 
A nanoluciferase was previously cloned downstream of the segment of the influenza 
genome encoding the polymerase acidic (PA) protein to create the luciferase-
expressing (Luc-) WSN/33 strain (Tran et al., 2013). Luc-WSN/33 was demonstrated to 
be equally as virulent as wild-type (WT) WSN/33; competently replicate within the same 
host range as WT WSN/33; and have high specific activity (light output) (Tran et al., 
2013). WT viruses were obtained from the sources listed in Table 1. Using standard 
reverse genetics (Hoffman et al., 2002), Luc-strains were generated from these WT 
strains prior to my thesis work. The influenza A genome consists of 8 negative-sense, 
single-stranded RNA segments, one of which encodes the HA protein and another 
encodes the NA protein. To create the reassortant, Luc-expressing strains, plasmids 
encoding the HA and NA gene segments from WT strains were generated and 
combined with plasmids encoding the remaining 6 influenza genome segments 
originating from Luc-WSN/33 (including the Luc-PA segment). Titers of the resulting 
reassortant strains were determined using the TCID/50 method.  
 
Table 1: Viral Strain Sources 
WT Virus Strain Abbreviation Source 
Influenza A/WSN/33 (H1N1) WSN/33 ATCC 
Influenza A/Wyoming/3/2003 
(H3N2) WY/03 
Dr. Arnold S. Monto; University of 
Michigan School of Public Health 
Influenza A/Ann Arbor/2017 
(H3N2) AA/17 
Dr. Arnold S. Monto; University of 
Michigan School of Public Health 
Influenza A/Hong 
Kong/4801/2014 (H3N2) HK/14 
Centers for Disease Control and 
Prevention International Reagent 
Resource 
 8 
Influenza A/Singapore/INFIMH-
16-0019/2016 (H3N2) Sing/16 
Centers for Disease Control and 
Prevention International Reagent 
Resource 
Influenza A/Wisconsin/67/2005 
(H3N2) WI/05 
Centers for Disease Control and 
Prevention International Reagent 
Resource 
Influenza A/California/07/2009 
(H1N1) CA/09 
Centers for Disease Control and 
Prevention International Reagent 
Resource 
 
 
Extracellular Vesicle Isolation and Quantification  
Mouse MHS AMs (ATCC) were plated on polystyrene flasks and grown to confluency in 
RPMI 1640 culture medium containing 10% FBS and penicillin/streptomycin. Once 
confluent, cells were lifted with trypsin 0.25%, pelleted using centrifugation (250 g for 5 
min) at 4 °C, resuspended in serum-free RPMI, plated onto fresh flasks, and incubated 
overnight. The resulting conditioned media was collected and depleted of cell debris 
and apoptotic bodies via serial centrifugation (500 g for 5 min followed by 2500 g for 12 
min) at 4°C. EVs were pelleted using ultracentrifugation (17,500 g for 30 min) at 4°C 
(Bourdonnay et al., 2015). The pelleted EVs were washed with PBS and pelleted again 
using ultracentrifugation (17,500 g for 30 min). The pelleted EVs were resuspended in 
PBS and aliquoted. EV concentration was quantified for each isolation using flow 
cytometry. EVs were identified and quantified by comparative size to calibration beads. 
EV concentration was determined by analysis using FlowJo software (FlowJo, LLC).  
 
Luciferase Assays for Real-time Quantification of Viral Replication 
To assay viral replication in Luc-expressing influenza strains (Luc-strain), for all 
luciferase assays, MDCKs were seeded at 90% confluency on flat-bottom 96-well plates 
in serum-containing medium overnight. Cells were then washed; infected with the 
appropriate reassortant strain; and provided Enduren luciferase substrate (Promega 
E6481) according to manufacturer’s instructions, with or without EVs or inhibitors diluted 
in VGM. Luminescence was read and recorded from each well at 90 second intervals 
using a Synergy H1 Luminescence Reader (BioTek) with CO2 regulator (BioTek) plate 
reader. Cells were kept at 37°C and 5% CO2 concentration during readouts. Readouts 
were taken until the first condition reached the end of the viral exponential growth phase 
(16-24 hours for all experiments) unless otherwise noted. All experiments were 
performed with a multiplicity of infection (MOI) of 1 unless otherwise noted.  
 
Viral replication luciferase data is presented as measurements of luminescence area 
under the curve (AUC) values. The AUC value represents the sum total of viral 
replication in a set period of time. AUC values were normalized to the control and 
averaged for each condition. Statistical analysis was performed between means of 
condition replicates unless otherwise noted. 
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Acidification Inhibitor IC50 Assay 
MDCK cells were pre-incubated for 30 min with the indicated concentrations of 
bafilomycin or chloroquine. Cells were subsequently co-incubated in VGM with 
the indicated Luc-strain, the same concentration of acidification inhibitor, and 
substrate. For a given 96-well plate, 4 strains with each dose of inhibitor were 
performed as triplicates. For these experiments, nonlinear regression was 
performed on AUC values and IC50 curves were calculated and generated for 
each condition using Prism 8 software. 
 
Endosomal Escape Assay  
MDCK cells were cooled on ice for 30 min, washed with ice-cold PBS, and 
incubated with the indicated Luc-stain diluted in VGM on ice for 45 min to allow 
virions to bind without being internalized. Cells were then washed with cold PBS 
to remove unbound virus. Cells were incubated with substrate in VGM at 37°C 
and 5% CO2 to initiate viral internalization. Bafilomycin was added to a final 
concentration of 10nM at the indicated time points, which refer to the duration of 
the incubation at 37°C and 5% CO2 prior to bafilomycin addition. Upon the final 
timed addition of bafilomcyin (80 min), cells were placed in the luminescence 
reader as described above. Replication was determined by luminescence 
measurements taken over the course of a total of 6 hours of infection time at 
37°C, so as to limit the assay to one replication cycle (World Health Organization 
[WHO], 2020).  
 
Immunofluorescence Microscopy 
Human A549 AECs were plated overnight at a density of 1.1e5 cells per well on 
fibronectin (Sigma; 1.25ug/cm2)-coated number 1.5 coverglass chamber slides (Lab-
Tek, Nunc) in RPMI supplemented with 5% FBS and streptomycin/penicillin. Cells were 
washed and co-incubated for 40 min with virus with EVs or PBS control in VGM. 
WSN/33 and HK/14 virus was given at a MOI of 1. Cells were washed with PBS, fixed 
with 4% paraformaldehyde in PBS (10 min @ RT), permeabilized with 0.1% Triton X-
100 (5 min @ RT), followed by an incubation in block solution (0.3M glycine, 2% BSA, 
and 5% goat serum) (45 min @ RT). Primary staining was performed as sequential 
overnight incubations at 4°C using rabbit anti-Rab7 for late endosomes (Cell Signaling 
Technologies, 9367) (1:100) followed by mouse anti-influenza NP (Abcam, ab20343) 
(2.89 ug/mL), in block solution. Secondary staining was performed sequentially and 
according to manufacturer specifications with Alexa Fluor 488 anti-mouse IgG (1:1000) 
followed by Alexa Fluor 568 anti-rabbit IgG (1:1000). Cells were covered with DAPI 
Prolong Gold mounting medium (Invitrogen). Images were taken from an SP5X inverted 
confocal microscope and analyzed with Application Suite Advanced Fluorescence 
Software (Leica). Images were captured with laser intensities and amplifier gains set to 
avoid pixel saturation. Fluorophores were independently excited and detected 
sequentially. Individual images were captured at a 100 objective with 1.4 numerical 
aperture, oil immersion, and pinhole set to 1 µm. Z stack images were captured at 
512x512 pixel resolution and were subsequently visualized and created with ImageJ 
software (National Institutes of Health). Virus nuclear localization was quantified as a 
ratio of NP intensity within the DAPI region divided by total cellular NP intensity. 
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Colocalization of influenza within late endosomes was quantified as the M2 
colocalization coefficient of NP and Rab-7 staining using the coloc 2 plugin in ImageJ.  
 
RESULTS 
 
Patient-derived, luciferase-expressing influenza strains are differentially sensitive 
to EVs in a HA-/NA-dependent manner  
 
WSN/33 is the quintessential lab-adapted influenza strain used for research studies. 
Initial unpublished findings of Schneider et al. used a WSN/33 strain previously 
constructed to express a luciferase reporter gene (Tran et al., 2013). This Luc-strain 
generates luminescence within infected cells with high specific activity and provides a 
time-integrated, high-throughput readout of competent viral replication. However, 
WSN/33 (and Luc-WSN/33) cannot infect humans or wild mice (Staeheli et al., 1988, 
Thangavel and Bouvier, 2014), and its mechanism of infection is unique from that of 
strains circulating in the human population (Goto et al., 1998). While both WT and Luc-
WSN/33 were demonstrated to be sensitive to inhibition by EVs in AECs via RT-qPCR 
and luciferase assays, respectively (Schneider et al., unpublished), it was therefore 
necessary to confirm the activity of EVs against clinically-relevant, patient-derived 
strains.  
 
Using standard reverse genetics (Hoffman et al., 2002), luciferase-expressing seasonal 
HK/14 and pandemic CA/09 strains were generated from primary isolates of these 
influenza strains. As described in Materials and Methods, the influenza A genome 
consists of 8 negative-sense, single-stranded RNA segments, one of which encodes the 
HA protein and another encodes the NA protein. Plasmids encoding the HA and NA 
gene segments from WT strains were generated and combined with plasmids 
composed of the remaining 6 influenza genome segments originating from Luc-WSN/33 
(including the luciferase-encoding segment). Known as the 6+2 reassortment strategy 
(Hoffmann et al., 2002), this method has the advantage of creating viruses differing only  
 
Fig. 1. EVs demonstrate a HA-/NA-
dependent inhibitory effect on influenza 
Quantification of viral replication of various 
Luc-strains. MDCK cells were co-incubated 
with the indicated Luc-strain (MOI = 1) and 
EVs (EV:cell = 2). Viral replication was 
quantified by luminescence readout and 
tracked over 16-24 h. Data represent mean 
luminescence AUC from individual wells 
normalized to mean AUC from untreated 
wells (dashed line) for a given Luc-strain. 
For each Luc-strain, significance between 
the mean AUC of EV-treated wells and that 
of untreated wells were calculated and 
depicted in the figure. Filled shapes and 
bars indicated strains determined to be sensitive to inhibition by EVs, while open shapes and bars 
indicate strains resistant to inhibition by EVs. n = 3 individual experiments with 6 replicates per condition 
per experiment. Error bars = SD.  
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by HA and NA, which are the major sources of variability in virulence between strains 
(Sakai et al., 2017). Additionally, replication of these strains can be tracked using 
luminescence as a high-throughput readout. Schneider et al. previously measured the 
inhibitory effect of EVs on the Luc-HK/14 and Luc-CA/09 strains in MDCK cells using 
luminescence readout to quantify viral replication. These experiments showed that Luc-
CA/09, but not Luc-HK/14 was inhibited by treatment of MDCK cells with EVs 
(Schneider et al., unpublished data). Given that these reassortant strains differ only in 
their expressed HA/NA, these preliminary results suggested that these surface proteins 
determine influenza strain sensitivity to the inhibitory effects of EVs.   
 
To validate these findings, we generated an expanded panel of reassortant viruses 
derived from patient-isolated strains (Table 1). Using the same method and analysis as 
before, we found that Luc-expressing WSN/33, WI/05, WY/03, and CA/09 strains (filled 
shapes) were susceptible to inhibition by EVs, but Luc-expressing AA/17, Sing/16, and 
HK/14 (open shapes) strains were resistant to this inhibition (Fig. 1). As with Luc-CA/09 
and HK/14, these seven strains differ only in their expressed HA/NA. Given the 
divergent sensitivity to inhibition by EVs displayed in this expanded panel of influenza 
strains, we concluded that EVs inhibit influenza replication at stage which depends on 
HA or NA. 
 
EVs prevent viral-endosomal fusion and subsequent trafficking to the nucleus  
 
To further characterize the effect of EVs on influenza, we sought to identify the stage of 
viral replication inhibited by EVs. Data in Fig. 1 suggested that EVs inhibit influenza 
infection at a stage that depends on HA or NA. Several stages of the influenza 
replication cycle require the proper functioning of HA and/or NA: plasma membrane 
binding, viral-endosomal fusion, virion assembly, and plasma membrane budding 
(Matsuoka et al., 2013). Additionally, data collected prior to this thesis demonstrated 
that EVs inhibit influenza in AECs at an intracellular stage of the viral replication cycle 
(Schneider et al., unpublished data). This inhibition occurs early (between 1-3 hours of 
infection) (Schneider et. al., unpublished data), suggesting that the later HA/NA-
dependent stages of the influenza replication cycle (assembly, budding, and release) 
are not the targets of EVs. Taken together, these data suggest that EVs inhibit influenza 
at the HA-dependent stage of viral-endosomal fusion. Consistent with this, EVs have 
been shown to be internalized by AECs into endosomes (Schneider et al., 2017), as in 
other cell types (Tian et al., 2013). Therefore, this led to the hypothesis that EVs inhibit 
HA-dependent endosomal fusion of influenza infection.  
 
To investigate the effect of EVs on endosomal fusion of influenza, we compared the 
effects of EVs on the localization of an influenza marker (influenza nucleoprotein [NP]) 
within late endosomes and nuclei for the representative EV-sensitive (WSN/33) and EV-
resistant (HK/14) strains. A549 AECs were co-incubated with the indicated strain and 
EVs for 40 minutes. This time point was chosen to visualize localization of influenza 
within late endosomes (Qin et al., 2019). We labeled cells with primary antibodies for 
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Fig. 2. EVs trap influenza in late endosomes. 
(A) A549 cells were co-incubated with WSN/33 or HK/14 for 40 min +/- EVs. Cells were washed, fixed, 
permeabilized, and stained with antibodies against influenza A NP (green) and the late endosomal 
marker Rab7 (magenta). Nuclei were also stained with DAPI (blue). Images shown are representative of 8 
independent experiments. (B) Localization of influenza to the nucleus is represented as a ratio of the 
intensity of NP staining colocalized within nuclei (NP:DAPI) to the total intensity of NP staining in the cell. 
Colocalization of influenza to late endosomes was quantified by measuring the Manders Coefficient of the 
influenza marker NP with the late endosomal marker Rab7. Individual data points represent values 
calculated from z stack images from individual cells. n = 8 individual experiments with > 5 z-stack images 
of individual cells per condition per experiment. Error bars = SD. 
 
 
 
 
 
 
 
A 
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influenza A NP and Rab7, a late endosomal marker. Localization of WSN/33 NP with 
nuclear (DAPI) and Rab7 markers was captured by immunofluorescence microscopy. 
Colocalization of NP with DAPI and Rab7 markers was quantified (Fig. 2B). Influenza 
within late endosomes was quantified by colocalization of NP with Rab7. NP localization 
within DAPI was used to quantify viral escape from the endosome and subsequent 
nuclear trafficking. In Figs. 2A, B, we demonstrated that treatment of AECs with EVs 
increased endosomal colocalization of WSN/33. As anticipated, there was no significant 
change in endosomal colocalization of HK/14 associated with treatment with EVs (Figs. 
2A, B). Consistent with these data, we demonstrated that EVs reduce detectable 
influenza NP within the nuclei of cells infected with WSN/33, but do not affect nuclear 
localization in cells infected with HK/14 (Figs. 2A, B).These results indicate that EVs 
inhibit replication of EV-sensitive influenza strains in AECs by prohibiting viral escape 
from late endosomes and subsequent trafficking to the nucleus. 
 
Influenza strains which are resistant to inhibition by EVs are affected by 
acidification inhibitors at later timepoints compared to EV-sensitive strains. 
 
Once internalized by the cell, influenza trafficks within endosomes. Endosomes undergo 
gradual acidification as they progress from early to late endosomes (Wiley and Skehel, 
1987). Acidification of the endosome triggers a conformational change in HA. This 
conformational change enables fusion of the viral envelope with the endosomal 
membrane and subsequent nuclear translocation of the virus. The pH of fusion has 
been suggested by several studies to be a major determinant of influenza pathogenicity 
(Gerlach et al., 2017; Zaraket et al., 2013), making this a puissant target for innate host 
defenses. Previous studies demonstrated that the pH range that enables influenza to 
fuse with the endosomal membrane differs for each strain (Galloway et al., 2013). Given 
our results and previous findings regarding an HA-determined pH of fusion, we 
hypothesized that EVs confine influenza to late endosomes by affecting endosomal 
acidification. Thus, endosomal pH would be sufficiently changed to prevent HA-
dependent endosomal fusion of certain strains, but permit the fusion of other strains. 
 
To investigate whether the differential sensitivity of influenza strains to treatment by EVs 
is related to differences in their pH of fusion, we characterized the dynamics of their 
escape from the endosome. Because endosomes undergo progressive acidification, the 
longer an influenza virion remains in an endosome, the lower the endosomal pH 
(Huotari and Helenius, 2011). Correspondingly, strains with a lower pH of fusion fuse 
later in endosomes (White and Whittaker, 2016). To qualify the difference in the pH of 
fusion of representative EV-sensitive and EV-resistant strains, we added high doses of 
the endosomal acidification inhibitor bafilomycin at discrete timepoints following viral 
internalization and tracked viral replication post-bafilomycin addition (Figs 3A, B). 
Because endosomes gradually acidify, viral replication post-bafilomycin addition is a 
readout of the virions that had already escaped from the endosome and progressed to 
subsequent steps of the viral replication cycle before endosomal acidification was 
halted. Therefore, in strains where replication is inhibited at early timepoints of 
bafilomycin addition, this would indicate that endosomal fusion of these strains occurs at 
a higher pH than strains inhibited by later timepoints of addition. 
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Fig. 3. Influenza strains resistant to treatment with EVs escape the endosome at earlier timepoints 
than strains susceptible to inhibition by EVs. 
MDCK cells were pre-treated 
with the indicated Luc-strain on 
ice for 30 min to permit viral 
binding but prohibit 
internalization, washed, then 
brought to 37°C to permit 
synchronous internalization of 
virus at time 0. 10nM of 
bafilomycin were added at the 
indicated timepoints post-
internalization and viral 
replication was quantified by 
luminescence. (A, B) 1 
experiment representative of 5 
individual experiments is shown 
for each strain. Results are 
expressed as mean AUC 
normalized to vehicle control 
(dashed line). (C, D) Kinetics of 
endosomal escape are 
depicted by loss of inhibition by 
bafilomycin. Results are 
expressed as the rate of viral replication relative to vehicle control from (C) 0-20 min or (D) 60-80 min 
post-bafilomycin addition. Data points represent mean slope (change in % inhibition/time interval) for 
each experiment. Bars represent the mean of each experimental average within a condition. n = 5 
individual experiments with 5 replicates per viral condition per experiment. Error bars = SEM.  
 
Fig. 4. Influenza strains resistant to 
treatment with EVs are inhibited by 
acidification inhibitors at lower doses 
than strains susceptible to inhibition by 
EVs. 
Replication of various Luc-strains in MDCK 
cells primed and co-incubated with the 
indicated concentration of acidification 
inhibitors (A) bafilomycin or (B) chloroquine 
was quantified. Curves with filled shapes  
filled bars indicate EV-sensitive strains, 
while curves with open shapes and open 
bars indicate EV-resistant strains. AUC 
values were calculated and averaged 
among 3 replicates per condition within an 
individual experiment. Results represent 
the mean of the average AUC from 
individual experiments for a given condition. 
n > 3 individual experiments. Error bars = 
SEM. 
 
Figs. 3A, B demonstrate representative endosomal escape assays of EV-sensitive 
(filled bars) and EV-resistant (open bars) Luc-expressing influenza strains. As indicated 
by Figs. 3A, B, immediate bafilomycin addition inhibited the replication of all Luc-  
expressing influenza strains by at least 80%, demonstrating that all strains require some 
degree of endosomal acidification to escape the endosome and progress through the 
A 
B 
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replication cycle. Bafilomycin addition at and beyond 20 minutes had no ability to inhibit 
the replication of both EV-sensitive strains, Luc-WSN/33 and Luc-WI/05 (Figs. 3A, B), 
indicating that all virions had escaped the endosome within 20 min. Conversely, 
replication of the EV-resistant Luc-HK/14 and Luc-AA/17 was inhibited at 20 min post-
internalization and continued to exhibit some level of inhibition when bafilomycin was 
added at 60 min, demonstrating that these strains escaped the endosome later than 
Luc-WSN/33 and Luc-WI/05. 
 
The slope of the change in inhibition was also calculated in order to quantify this 
differential timing of endosomal escape across all experiments. As shown in Figs. 3C, 
D, EV-sensitive strains exhibited significantly more endosomal escape within 20 
minutes post-internalization compared to EV-resistant strains. Conversely, EV-sensitive 
strains demonstrated no late (60-80 minutes post-internalization) endosomal escape, 
while EV-resistant strains continued to exhibit escape at this late timepoint. 
Cumulatively, these data demonstrate that EV-sensitive strains escape endosomes 
earlier than EV-resistant strains. This suggests that EV-sensitive strains have a higher 
pH of fusion than EV-resistant strains. 
 
Influenza strains which are resistant to inhibition by EVs are sensitive to 
acidification inhibitors.  
  
To more completely qualify the difference in the pH of fusion of the Luc-strains used in 
in Fig. 1, we investigated their sensitivity to inhibition by bafilomycin as well as an 
additional endosomal acidification inhibitor known as chloroquine. We hypothesized that 
the replication of strains with a higher pH of fusion would be inhibited at lower doses of 
the acidification inhibitors than strains which require a lower pH to fuse with the 
endosomal membrane. MDCK cells were pre-incubated for 30 mins with the indicated 
concentration of bafilomycin (Fig. 4A) or chloroquine (Fig. 4B). Cells were subsequently 
co-incubated with the indicated Luc-stain and acidification inhibitor. Replication of EV-
resistant strains (open shapes and bars, Figs. 4A, B) was reduced by 50% at 
bafilomycin and chloroquine concentrations at or below 1.25nM and 10μM, respectively, 
while the inhibition of EV-sensitive strains (filled shapes and bars, Figs. 4A, B) required 
1.5nM and 20uM of bafilomycin and chloroquine, respectively, to reach this level of 
inhibition. These results demonstrate that EV-sensitive strains require higher doses of 
endosomal acidification inhibitors to inhibit replication to the same extent as EV-
resistant strains. Furthermore, these results support our hypothesis that the pH of fusion 
for EV-sensitive strains is higher than that of EV-resistant strains. 
 
DISCUSSION 
 
Various protective roles of AMs in influenza infection have been described, including 
their secretion of pro-inflammatory cytokines, ingestion of apoptotic bodies, and 
sequestration of the virus. However, the immobile nature and sparse concentration of 
AMs in the distal airways prompted the exploration of a role of AMs that had yet to be 
explored in the context of influenza infection: that of AM paracrine signaling via EVs. 
Unpublished data (Schneider et al.) which preceded the experiments in this honors 
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thesis demonstrated that EVs inhibited influenza at a stage in the viral replication cycle 
which was both intracellular and HA-/NA-dependent. This led us to hypothesize that 
EVs inhibit influenza replication in AECs at the HA-dependent stage of viral-endosomal 
fusion. In this thesis, we first confirmed preliminary results demonstrating the differential 
sensitivity of influenza to treatment with EVs in an expanded panel of influenza strains 
differing solely in HA/NA. We then sought to characterize the effect of EVs on viral-
endosomal fusion by analyzing the colocalization of influenza NP with a late endosomal 
marker. We found that treatment of AECs with EVs increased localization of a 
representative EV-sensitive, but not EV-resistant, strain to late endosomes. 
Correspondingly, treatment with EVs prohibited a representative EV-sensitive strain 
from entering the nucleus. Furthermore, we characterized the effect of various doses 
and timed addition of acidification inhibitors on viral replication and found that the strain 
sensitivity to EVs closely followed trends in the different optimal pH of fusion of these 
strains. We concluded that EVs inhibit viral-endosomal fusion and suggest that this 
inhibition is a result of accelerating endosomal acidification. Taken together, our results 
demonstrate that EVs target a puissant step in the replication cycle of many enveloped 
viruses and may be an important host defense against infection by this subset of 
viruses.   
 
Previous findings demonstrated an HA-dependent difference in the optimal pH of fusion 
of influenza strains (Galloway et al., 2014; Singanayagam et al., 2019). By 
characterizing the timing of endosomal escape and acidification inhibitor dose response 
of our various strains, our findings supported the conclusion that different strains have 
different pH of fusions. Furthermore, our data suggested that EV-sensitive strains 
require a higher pH of fusion than EV-resistant strains. The most likely explanation for 
these observed trends is that EVs act to decrease endosomal pH in recipient cells. 
Thus, it is possible that treatment of infected cells with EVs accelerates endosomal 
acidification such that the endosomal pH falls beneath the range tolerated for fusion of 
susceptible strains with the endosomal membrane. Consequently, these strains are 
trapped in late endosomes and likely ushered to the ultimate destination for many 
endosomes: lysosomal degradation. In this model, acceleration towards a lower pH 
would have a neutral effect on the replication of resistant strains, as was demonstrated 
in Fig. 1. In the hopes of validating the model suggested here, future experiments may 
be performed to establish pH differences in endosomes containing EVs versus those 
that do not contain EVs. 
 
The pH stability of a strain’s HA defines several important characteristics of a virus’ 
replication cycle and, consequently, the course of infection. The pH stability of HA and 
its pH optimum of endosomal fusion have been demonstrated to be major determinants 
in strain-specific influenza pathogenicity (Gerlach et al., 2017), transmissibility (Zhong et 
al., 2014; Schrauwen and Fouchier, 2014; Russier et al., 2016), and host-specificity 
(Galloway et al., 2013; Zaraket et al., 2013). Strains with mutations in regions of HA 
critical for endosomal fusion and which lead to a higher optimal pH of fusion evade 
inhibition by the host antiviral interferon response more efficiently (Gerlach et al., 2017) 
and replicate more rapidly (Singanayagam et al., 2019). However, HA subtypes with a 
higher optimal pH of fusion have also been shown to undergo premature HA activation 
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when exposed to an acidic environment mimicking the upper respiratory tract 
(Singanayagam et al., 2019). Therefore, it is possible that strains with a high optimal pH 
of fusion have evolved to evade the interferon response. However, these strains may 
subsequently succumb to another layer in the host’s innate immune response: the 
antiviral action of EVs. Importantly, it has been suggested that the high optimal pH of 
fusion of many avian influenzas is partly responsible for the inability of these viruses to 
cross to the human species effectively (Singanayagam et al., 2019). Furthermore, more 
epidemiologically-relevant strains, including avian and pandemic influenzas, have been 
shown to fuse with the endosome at higher pH values than seasonal strains (Russier et 
al., 2016). Because of their high pH of fusion, these strains are likely capable of 
circumventing the host’s interferon defenses. However, our studies have demonstrated 
a mechanism by which the host may combat infection of AECs with these more 
epidemiologically-relevant strains by exploiting their relatively high pH of fusion. Thus, 
our study has helped illuminate the host’s ability to target a subset of influenza strains 
which may circumvent the host’s antiviral interferon response.    
 
Previous studies suggest that EVs isolated from tracheobronchial epithelial cells prevent 
influenza infection of ECs by binding to influenza extracellularly through sialic acid 
residues on the surface of these non-AM-EVs (Kesimer et al., 2009). This thesis and its 
preliminary studies demonstrated a clear intracellular inhibitory action of EVs on 
influenza in ECs, specifically at the point of viral-endosomal fusion. The differences 
between the antiviral activities demonstrated in previous studies versus those 
demonstrated in this thesis are likely due to differences in the cell type origin of the EVs. 
Thus, our study in combination with that of Kesimer et al. (2009) suggests that different 
airway regions within the host have developed distinct innate host defenses against 
influenza.  
 
While we have classified the effect of EVs on influenza infection here, there remain 
several unknowns regarding the source of influenza resistance imparted to AECs by 
EVs. For example, the molecular mediator(s) of this antiviral activity have yet to be 
identified. Schneider et al. has determined the source of this activity is not RNA-based 
and is likely one or multiple proteins or lipids. Because the responsible molecule(s) have 
yet to be identified, efforts to characterize a precise mechanism of action are somewhat 
limited. Future studies will seek to identify the mediator(s) of this activity via depletion of 
targeted lipid(s) and proteomic analysis. Additionally, the effect of AM infection on the 
cell’s packaging of this antiviral molecule(s) has yet to be determined. If future studies 
demonstrate that infection of the AM alters its secretion of this antiviral cargo, this would 
suggest influenza has a possible means of combating this host defense in vivo.  
Identification of the antiviral molecule(s) in EVs as well an understanding of its 
packaging by AMs during an infection and its antiviral mechanism in the host could 
prove useful in the development of antiviral therapies and preemptive measures.  
 
Currently, influenza vaccines are only 14-60% effective (CDC, 2020), and their 
effectiveness is dependent upon the proper identification of 3-4 strains estimated to be 
the most virulent in a given season and chosen as targets for the vaccine. Several 
vaccines employ adjuvants – ingredients used to elevate the recipient’s immune 
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response for the purpose of improving the effectiveness of the vaccine. Currently, most 
influenza vaccines do not contain adjuvants (CDC, 2018). However, our discovery and 
characterization of a host defensive measure against influenza infection may lead to 
further exploration in host immunity against influenza such that addition of adjuvants to 
the seasonal influenza vaccine may become an obvious next step to improving 
preemptive measures. Furthermore, the antiviral cargo whose effects we have 
described here may prove useful as a treatment for not only influenza, but other 
relevant pathogens internalized into endosomes.  
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